Amid ongoing debate over biosimilar use in the United States, a new government analysis found that Medicare Part D spending on biologic medicines in 2019 could have been reduced by $84 million, or 18%, if they had been used more frequently — and beneficiaries themselves could have saved $1.8 million.
The potential savings were minimized because not all Medicare Part D health plans covered biosimilars, which are nearly identical variants of pricey biologic medicines that yield the same health outcomes. And the health plans that did cover biosimilars “rarely encouraged” prescribing, the analysis noted. Instead, the plans favored costlier, brand-name biologics on formularies, or lists of covered medicines.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
